Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Xbrane Biopharma AB

XBRANE.ST ✓ COMPLIANTFree checks used up today ☆ Track — members

Europe · Healthcare · Biotechnology & Medical Research ·

Sweden Micro Cap Analyst: N/A

Last Close

$1.34

▲ +1.15%

Market Cap $28.12M · Vol 96.30K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$28.12M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

54.55

Momentum

Beta

1.34

vs Market

52W High

$2.04

33.10% below

52W Low

$0.55

131.63% above

Volume

96.30K

Avg 166.41K

P/B

0.37

Price-to-book

ROE

33.08%

Return on equity

Free Float

60.38%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Xbrane Biopharma AB (XBRANE.ST) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does XBRANE.ST pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-24.43%

+26.44%

+28.29%

+19.55%

YTD

+28.92%

+21.76%

-95.68%

-99.21%

Financials & Valuation

TTM · Annual

Total Revenue	$16.56M
Net Income	$-5,018,698.00
Revenue Growth (YoY)	+17.14%
Gross Margin	58.77%
Operating Margin	-13.08%
Net Profit Margin	-30.30%
ROE	33.08%
ROA · ROIC	-5.80% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.38
P/B	0.37
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	20.61M

Technical Indicators

50-Day SMA	$1.18
200-Day SMA	$1.02
RSI (14)	54.55
Beta	1.34
52-Week High	$2.04
52-Week Low	$0.55

Volume Today	96.30K
Avg Daily Volume (30D)	166.41K
Relative Volume	0.58x
Volatility (10D)	216.08
Volatility (30D)	150.65
Free Float	60.38%

Analyst Consensus

N/A

Current Price $1.34

Mean Target $1.72

52W Low$0.55 52W High$2.04

Current

Target

$0.55 $2.04

Current Analyst target

+27.95% upside potential · 0 analysts

Identifiers

ExchangeEurope

FIGIBBG00BV3XZK8

ISINSE0026598583

CountrySweden

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.62% ONC BeOne Medicines AG -1.74% 068270.KS Celltrion, Inc. +5.32% MEDP Medpace Holdings, Inc. +2.37% CRL Charles River Laboratories International, Inc. +3.94%

Company Profile

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.